KinderHook Industries Acquires Enhabit for $1.2B in Take-Private Deal

In one of 2025's first major healthcare transactions, KinderHook Industries announced today it will acquire Enhabit, Inc. (NYSE: EHAB) for approximately $1.2 billion in an all-cash transaction. The deal, valuing shares at $10.25 each, represents a 34.2% premium to Enhabit's closing price on January 10, 2025, and takes the publicly-traded home health and hospice provider private in a strategic bet on the sector's demographic tailwinds.

The transaction comes as private equity firms increasingly target home healthcare platforms, anticipating surging demand as Baby Boomers age and healthcare delivery models shift away from expensive institutional settings. For KinderHook, a middle-market private equity firm with over $3 billion in assets under management, the acquisition represents its largest platform investment to date and a bold entry into the fragmented post-acute care market.

Under terms of the definitive agreement, Enhabit shareholders will receive $10.25 per share in cash—a significant premium that values the company's equity at roughly $1.2 billion. Including assumed debt and other liabilities, the enterprise value climbs higher, though exact figures were not disclosed in the official announcement.

The premium represents a compelling offer for Enhabit shareholders who have weathered volatility since the company's 2022 spin-off from Encompass Health Corporation. Enhabit's stock had traded as high as $18 in late 2022 but faced headwinds from Medicare reimbursement pressures and labor cost inflation throughout 2023 and 2024.

KinderHook's interest in Enhabit aligns with the firm's established healthcare investment thesis. The private equity shop has built a portfolio of healthcare services businesses, focusing on companies that benefit from favorable regulatory environments, demographic trends, and opportunities for operational improvement—all boxes that Enhabit checks.

Headquartered in Dallas, Texas, Enhabit operates one of the nation's largest home health and hospice platforms, with approximately 250 locations across 34 states. The company provides skilled nursing, physical therapy, occupational therapy, speech-language pathology, medical social work, and hospice care services to patients recovering from illness, injury, or surgery in their homes.

In its most recent fiscal year, Enhabit generated approximately $1.1 billion in revenue, serving roughly 95,000 patients annually. The company's business model relies heavily on Medicare reimbursements, which account for approximately 85% of revenues—a factor that brings both stability and regulatory exposure.

The company's geographic footprint is strategically concentrated in Sun Belt states with rapidly aging populations, including Texas, Florida, and Arizona. This positioning provides a natural hedge against demographic shifts, as these regions are expected to see the fastest growth in Medicare-eligible populations through 2035.

Despite favorable long-term demographics, Enhabit has faced near-term operational challenges that likely made private equity ownership attractive. The company has grappled with nursing shortages that have constrained census growth, wage inflation that has compressed margins, and Medicare payment adjustments that failed to keep pace with cost increases.

These pressures manifested in disappointing financial performance relative to initial post-spin expectations. While revenue has grown modestly, profitability metrics lagged industry peers, creating strategic tension between investing for growth and delivering quarterly earnings.

Private ownership potentially allows management to make longer-term investments in recruiting infrastructure, technology platforms, and geographic expansion without the scrutiny that comes with quarterly earnings calls and activist shareholders.

Founded in 2010, KinderHook Industries has built a reputation as a sector-focused middle-market investor with particular expertise in healthcare services, business services, and food and consumer sectors. The firm typically targets companies with $10 million to $100 million in EBITDA, though the Enhabit acquisition represents a step up in scale.

The Enhabit deal marks KinderHook's most significant healthcare platform investment and signals the firm's confidence in the home health sector's growth trajectory. Within healthcare, KinderHook has historically focused on businesses that benefit from defensive characteristics—essential services with recurring revenue models and limited exposure to discretionary consumer spending.

KinderHook's operational approach typically emphasizes organic growth acceleration, strategic acquisitions to fill geographic gaps, and implementation of best practices across portfolio companies. In home health, this playbook could translate to technology investments that improve clinician productivity, targeted acquisitions in high-growth markets, and payer relationship optimization.

Industry observers expect KinderHook to pursue several value creation strategies following deal close:

**Geographic Expansion**: Enhabit's 34-state footprint leaves white space in several high-growth markets. Strategic tuck-in acquisitions could expand the company's presence in the Pacific Northwest, Mountain West, and select Midwest markets where demographic trends favor home health utilization.

**Technology and Analytics Investment**: Home health providers increasingly compete on clinical outcomes and cost-efficiency metrics that determine Medicare Advantage and managed care contract rates. Investments in predictive analytics, remote patient monitoring, and clinician scheduling optimization could improve both quality scores and operational margins.

**Payer Mix Optimization**: While Medicare provides stable baseline revenue, higher-margin opportunities exist in Medicare Advantage plans and commercial insurance contracts. KinderHook may push for deeper partnerships with MA plans, which reward providers that can demonstrate superior outcomes and cost management.

**Labor Model Innovation**: Nursing shortages represent the home health sector's most significant constraint. Creative solutions—including partnerships with nursing schools, enhanced recruiting in lower-cost markets, and task-shifting to nurse practitioners and physician assistants—could unlock census growth that has been labor-constrained.

The Enhabit acquisition arrives at an inflection point for home-based care. Multiple macro trends are converging to drive demand for home health services at unprecedented levels:

The demographic wave is well-documented: according to Census Bureau projections, Americans aged 65 and older will grow from 58 million today to approximately 73 million by 2030—a 26% increase in just five years. This cohort consumes healthcare services at roughly three times the rate of younger populations.

Simultaneously, the healthcare delivery system is undergoing structural transformation. Medicare Advantage plans, which now cover 51% of Medicare beneficiaries, incentivize lower-cost care settings. Home health episodes cost roughly one-third of skilled nursing facility stays and one-tenth of hospital rehabilitation, making them attractive to MA plans managing total cost of care.

Hospital systems are also embracing home-based care models. The CMS Acute Hospital Care at Home waiver program, launched during COVID-19 and recently made permanent, allows hospitals to provide acute-level care in patients' homes. Over 300 hospitals now participate, creating referral opportunities and partnership models for home health providers.

KinderHook is far from alone in targeting the home health sector. Private equity investment in home-based care has accelerated dramatically since 2020:

In 2021, Clayton, Dubilier & Rice acquired Kindred at Home (now Centerwell Home Health) for $8 billion, combining Kindred Healthcare's home health division with insurer Humana's home care assets. That same year, Advent International and Warburg Pincus took home infusion provider Option Care Health private in a $3.5 billion transaction before returning it to public markets.

More recently, private equity has targeted smaller platforms for consolidation plays. TPG acquired Aveanna Healthcare in 2021, while Welsh, Carson, Anderson & Stowe has built a substantial home health portfolio through companies like Compassus and BrightSpring Health Services.

These investments reflect private equity's conviction that home health represents a rare combination of defensive characteristics, growth potential, and fragmentation that allows for value creation through consolidation and operational improvement.

The transaction has been unanimously approved by Enhabit's Board of Directors and is expected to close in the second quarter of 2025, subject to customary closing conditions including shareholder approval and regulatory clearances.

Given Enhabit's size and market position, the deal will likely undergo Hart-Scott-Rodino antitrust review, though approval is expected to be straightforward. The home health market remains highly fragmented—the top 10 providers collectively hold less than 25% market share—which should alleviate concentration concerns.

Healthcare investment bank J.P. Morgan Securities LLC is serving as financial advisor to Enhabit, while Wachtell, Lipton, Rosen & Katz is providing legal counsel. KinderHook is being advised by Kirkland & Ellis LLP on legal matters.

Following close, Enhabit will delist from the New York Stock Exchange and operate as a private company within KinderHook's portfolio. The companies have not disclosed whether existing management, including CEO Barb Jacobsmeyer, will remain in their current roles, though continuity is typical in healthcare services transactions where operational expertise is critical.

The KinderHook-Enhabit deal sends several important signals to healthcare investors and operators:

First, it demonstrates continued private equity appetite for scale platforms in defensive healthcare subsectors, even as broader M&A markets face headwinds from higher interest rates and economic uncertainty. Home health's recurring revenue, Medicare reimbursement stability, and demographic tailwinds make it an attractive asset class for financial buyers.

Second, the transaction validates the take-private thesis for healthcare services companies facing near-term operational challenges but possessing strong long-term fundamentals. Public market investors increasingly lack patience for multi-year turnarounds, creating opportunities for private equity to acquire quality assets at reasonable valuations.

Third, the deal may catalyze further consolidation in the fragmented home health sector. With thousands of small, independent providers still operating, Enhabit under private ownership could become an aggressive acquirer, using KinderHook's capital and M&A expertise to build out its footprint.

For Enhabit employees and patients, the transition to private ownership should be largely seamless. Home health is an operationally intensive, locally-delivered business where success depends on recruiting and retaining clinical talent, managing payer relationships, and delivering quality outcomes—fundamentals that don't change based on ownership structure.

The question for KinderHook will be whether the firm can execute on the strategic initiatives that public ownership constrained. With patient capital, operational expertise, and a portfolio of healthcare companies to share best practices, the private equity firm is positioning itself to capitalize on one of healthcare's most compelling secular growth stories.

As America ages and healthcare delivery continues shifting toward lower-cost settings, home health providers like Enhabit are increasingly central to the healthcare ecosystem. KinderHook's $1.2 billion bet reflects confidence that the sector's best days lie ahead—and that private ownership provides the optimal structure to capture that upside.